[Home ] [Archive]   [ فارسی ]  
Main Menu
Home::
Journal Information::
Archive ::
For Authors::
For Reviewers::
Ethical Code::
Subscription::
Contact us::
Peer Review Process::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
:: Volume 1, Issue 2 (7-2017) ::
Ir J Physiol Pharmacol 2017, 1(2): 122-116 Back to browse issues page
Development of Arsenic trioxide-induced hepatotoxicity model in mice according to the treatment protocol of acute promyelocytic leukemia
Saeedeh Sattaee Mokhtari , Shahriar Dabiri , Mahmoud-Reza Heidari , Ali Mandegary *
1. Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, IranGastroenterology and Hepatology Research Center, Institue of Basic and Clinical Physiology, Kerman University of Medical Sciences, Kerman, Iran
Abstract:   (14942 Views)
Background and aim: Arsenic trioxide (ATO) is used in treatment of APL. One of the major side effects of this drug is liver toxicity. So, introduction of an animal model for this toxic effect could be useful to evaluate hepato-protective compounds. As different hepatotoxic doses of arsenic have been reported in the literature, in this study we decided to develop a model of liver toxicity based on the protocol of ATO therapy in APL patients.
Methods: Considering the protocol of ATO therapy in APL patients (0.14 mg/day for 21 days) and FDA-suggested formula for dose translation between humans and animals, dose 1.7 mg/kg/day was used. To achieve the best time to take ATO administered without causing mortality, ATO was administered for 10 and 21 days to the male mice. At the end of the treatment period, liver tissue samples were dissected and then homogenized in physiologic buffer. The oxidative stress parameters including catalase and superoxide dismutase activity, lipid peroxidation and antioxidant capacity of the samples were determined using standard protocols. Damage to the liver tissue was determined by histopathological studies.
Results: Histopathological examinations indicated severe damage to the liver in the 21-day treated period. The damage was accompanied with significant increase in the lipid peroxidation (p < 0.05), catalase activity (p < 0.05), and superoxide dismutase activity (p < 0.01) in the ATO treated mice for 21days.
Conclusion: Treatment of mice with ATO 1.7 mg/kg for 21 days could resemble ATO-induced hepatotoxicty in human.

 
Keywords: Arsenic trioxide, Liver toxicity, Oxidative stress
Full-Text [PDF 1232 kb]   (2572 Downloads)    
Type of Study: Original Research | Subject: Gastrointestinal System
Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mokhtari S S, Dabiri S, Heidari M, Mandegary A. Development of Arsenic trioxide-induced hepatotoxicity model in mice according to the treatment protocol of acute promyelocytic leukemia. Ir J Physiol Pharmacol 2017; 1 (2) :122-116
URL: http://ijpp.phypha.ir/article-1-261-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 1, Issue 2 (7-2017) Back to browse issues page
مجله فیزیولوژی و فارماکولوژی ایران Iranian Journal of Physiology and Pharmacology
Persian site map - English site map - Created in 0.11 seconds with 36 queries by YEKTAWEB 4645